Article

Bone loss induced by ovariectomy in rats is prevented by gene transfer of parathyroid hormone or an Arg-Gly-Asp-containing peptide.

National Laboratory of Protein Engineering and Plant Genetic Engineering, College of Life Sciences, Peking University, Beijing, 100871, P.R. China.
Biotechnology Letters (Impact Factor: 1.74). 02/2005; 27(1):41-8. DOI: 10.1007/s10529-004-6577-2
Source: PubMed

ABSTRACT Osteoporosis is a major and growing healthcare concern as the population ages. The genes of both a Arg-Gly-Asp (RGD)-containing peptide and parathyroid hormone (PTH) were used to reduce bone loss induced by ovariectomy (OVX) in rats. Plasmids with either RGD or PTH gene were delivered into the quadriceps of OVX rats. The expression of the genes was detected by RT-PCR and radioimmunoassay. Analysis of bone mineral density, bone mechanical testing and bone mineral content indicated an improvement in bone properties in both RGD-transferred and PTH-transferred rats compared to OVX rats. Gene transfer of either RGD or PTH is therefore a possible approach to prevent bone loss in OVX rats thus providing a potential method to prevent osteoporosis in clinical situations.

0 Followers
 · 
68 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteoporosis is considered one of the most common and serious problems affecting the elderly population worldwide. It is a chronic and progressive disease, characterized by decreased bone mass and degeneration of the microarchitecture of the bone tissue. Gene therapy represents a new approach in osteoporosis treatment, and its main function is to restore the compromised function in the metabolism. This review aims to elucidate the main studies on gene therapy in recent years, in the medical databases, that use gene therapy for the treatment of osteoporosis in animal models, as well as the future Universidade Federal de São Paulo - UNIFESP Study conducted at the Interdisciplinary Center of Gene Therapy of UNIFESP/CINTERGEN Mailing address: Departamento de Morfologia e Genética, Disciplina de Histologia e Biologia Estrutural, UNIFESP, Rua Botucatu, 740, 2º andar, Edifício Lemos Torres, Vila Clementino, São Paulo, SP, Brazil, CEP: 04023-900. E-mail: rafa.pacheco@ig.com.br Work received on 10/8/2008 and approved on 4/26/2009 prospects of this therapy. The majority of the studies use the BMP, PTH and OPG genes, in an attempt to reestablish bone mass. Despite the lack of new molecules, all genes employed in these studies have proven to be efficient in the treatment of the disease. The benefits that gene therapy will provide for patients in the future should contribute substantially to increasing the quality of life for the elderly. Soon, clinical trials involving humans will benefit individuals with osteoporosis.
    Acta Ortopédica Brasileira 01/2011; · 0.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: abStract Osteoporosis is considered one of the most common and serious problems affecting the elderly population worldwide. It is a chronic and progressive disease, characterized by de-creased bone mass and degeneration of the microarchitecture of the bone tissue. Gene therapy represents a new approach in osteoporosis treatment, and its main function is to restore the compromised function in the metabolism. This review aims to elucidate the main studies on gene therapy in recent years, in the medical databases, that use gene therapy for the treat-ment of osteoporosis in animal models, as well as the future Work received on 10/8/2008 and approved on 4/26/2009 prospects of this therapy. The majority of the studies use the BMP, PTH and OPG genes, in an attempt to reestablish bone mass. Despite the lack of new molecules, all genes employed in these studies have proven to be efficient in the treatment of the disease. The benefits that gene therapy will provide for pa-tients in the future should contribute substantially to increasing the quality of life for the elderly. Soon, clinical trials involving humans will benefit individuals with osteoporosis.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bone development, regeneration and maintenance are governed by osteogenic differentiation processes from mesenchymal stem cells through to mature bone cells, which are directed by local growth and differentiation factors and modulated strongly by hormones. Mesenchymal stem cells develop from both mesoderm and neural crest and can give rise to development, regeneration and maintenance of mesenchymal tissues, such as bone, cartilage, muscle, tendons and discs. There are only limited data regarding the effects of hormones on early events, such as regulation of stemness and maintenance of the mesenchymal stem cell pool. Hormones, such as estrogens, vitamin D-hormone and parathyroid hormone, besides others, are important modulators of osteogenic differentiation processes and bone formation, starting off with fate decision and the development of osteogenic offspring from mesenchymal stem cells, which end up in osteoblasts and osteocytes. Hormones are involved in fetal bone development and regeneration and, in childhood, adolescence and adulthood, they control adaptive needs for growth and reproduction, nutrition, physical power and crisis adaptation. As in other tissues, aging in mesenchymal stem cells and their osteogenic offspring is accompanied by the accumulation of genomic and proteomic damage caused by oxidative burden and insufficient repair. Failsafe programs, such as apoptosis and cellular senescence avoid tumorigenesis. Hormones can influence the pace of such events, thus supporting the quality of tissue regeneration in aging organisms in vivo; for example, by delaying osteoporosis development. The potential for hormones in systemic therapeutic strategies is well appreciated and some concepts are approved for clinical use already. Their potential for cell-based therapeutic strategies for tissue regeneration is probably underestimated and could enhance the quality of tissue-engineering constructs for transplantation and the concept of in situ-guided tissue regeneration. Expert Rev. Endocrinol. Metab. 2(1), 59–78 (2007) Mesenchymal stem cells (MSCs) give rise to mature mesenchymal tissues such as bone, car-tilage, fat and muscle. MSCs are partially com-mitted mesenchymal precursors. Their early fate decision is influenced by program-induc-ing growth and differentiation factors. The influence of hormonally active compounds on MSCs and their early fate decision has rarely been addressed in experimental research, while there are abundant data regarding the steps fol-lowing early commitment that are targeted by hormones. In particular, the osteogenic path-way of differentiation is influenced strongly by hormones, including at least some very early events. This review will focus on the present knowledge regarding the influence of hor-mones on the differentiation events from MSCs through to mature bone cells. To estab-lish a semantic basis on the various terms used, we will start off with some paragraphs of defi-nitions on hormones, stem cells, stemness and stem-cell niches.
    Expert Review of Endocrinology &amp Metabolism 01/2007; DOI:10.1586/17446651.2.1.59

Preview

Download
2 Downloads
Available from